-
Ranolazine, HBV, and TBK1–Autophagy: Evidence Review
2026-10-05
This overview separates established ranolazine pharmacology from emerging HBV biology. The supplied 2025 study identifies an HBsAg–TBK1 mechanism linking impaired type I interferon signaling with incomplete autophagy, but it does not test ranolazine; any connection between ranolazine’s metabolic effects and HBV-associated TBK1 signaling therefore remains a research hypothesis rather than a published finding.
-
Fluorescein Tyramide in Oxytocin Circuit Research
2026-10-05
Fluorescein Tyramide is a fluorescent labeling dye used conceptually for high-sensitivity tissue and cell detection. This overview examines how signal amplification could support research on oxytocin-related defensive circuits while separating supplier claims from the findings and limitations of a 2026 mouse study.
-
Idoxuridine: Reading Mechanism Without Overreach
2026-10-04
Idoxuridine, also known as 5-iodo-2'-deoxyuridine, is a research-use antiviral nucleoside analog for investigating viral DNA synthesis. This evidence-focused guide explains how to interpret DNA replication disruption, product provenance, and translational findings without confusing mechanistic plausibility with clinical proof.
-
GOT2, Redox Shuttle, and Doxorubicin Cardiotoxicity
2026-10-03
A 2025 Phytomedicine study identifies GOT2 as a mechanistic target through which salvianolic acid A may reduce doxorubicin-induced myocardial injury. Its multi-level evidence connects GOT2, the malate-aspartate NADH shuttle, mitochondrial function, oxidative damage, and cardiomyocyte apoptosis, while remaining limited to preclinical models.
-
Ibrutinib (PCI-32765): BTK Research Workflow
2026-10-02
Build reproducible B-cell receptor signaling inhibition assays with Ibrutinib (PCI-32765), from solvent preparation through phospho-BTK and viability readouts. This workflow emphasizes covalent target engagement, CLL-relevant microenvironment models, assay controls, and practical troubleshooting rather than relying on a single IC50 value.
-
CHIR-99021 (CT99021) HCl Protocol Guide
2026-10-01
CHIR-99021 (CT99021) HCl provides a practical small-molecule approach for experimentally perturbing GSK-3α/β in stem-cell, signaling, metabolic, and T-cell workflows. In the absence of directly matched paper evidence, it should be used for model-specific pathway and dose-response optimization rather than as a universal cellular dose, clinical treatment, or validated substitute for experimental controls.
-
Quinolone–Coumarin Hybrids Against Toxoplasma gondii
2026-10-01
The 2024 Acta Parasitologica study evaluated 12 quinolone–coumarin hybrids derived from fluoroquinolones and novobiocin against Toxoplasma gondii in vitro. QC1, QC3, QC6, and novobiocin showed favorable activity–toxicity profiles, providing a useful phenotypic framework for prioritizing antiparasitic leads while emphasizing that the molecular target remains unresolved.
-
Streptavidin – Cy5 for Breast Cancer Assays
2026-09-30
Translate USP42 pathway findings into practical imaging and cytometry workflows with Streptavidin – Cy5. Its far-red Cy5 fluorescent dye supports sensitive biotin detection across immunofluorescence, immunohistochemistry, and flow cytometry while preserving flexibility for multiplex assay design.
-
Mitochondrial Calcium Signaling Represses Ferroptosis
2026-09-30
The reference study identifies mitochondrial calcium uptake through MCU as an upstream regulator of GPX4 activity and ferroptosis resistance. Its genetic, structural, and tumor-model evidence connects mitochondrial metabolism to GPX4 K90 acetylation, while also showing that MCU loss can suppress tumor growth and increase dependence on antioxidant protection.
-
GCN2, ZAKα, and Translational Control in Macrophages
2026-09-29
The reference study identifies GCN2-dependent eIF2α phosphorylation as a checkpoint that restrains excessive translation and ZAKα-driven inflammatory activation in macrophages. Its combination of translation assays, polysome profiling, proteomics, genetic perturbation, and pharmacological validation provides a framework for studying how ribosomal stress shapes inflammatory outputs.
-
TNFα–VASN Signaling in Glioma Stem Cell Self-Renewal
2026-09-29
A study in Neuro-Oncology identifies a context-dependent role for low tumor necrosis factor α (TNFα) in sustaining glioma stem cell self-renewal. Its integrated spatial, transcriptomic, metabolic, and in vivo evidence implicates Vasorin-mediated glycolysis and lactate-dependent macrophage feedback as a therapeutic vulnerability in glioblastoma.
-
MVC Uses RhoA/ROCK1 to Open Tight Junctions
2026-09-28
Ren and colleagues link MVC capsid protein VP2 to ROCK1 and show that early RhoA/ROCK1/MLC2 signaling disrupts tight junctions, redistributes Occludin, and supports viral infection in canine cells. The work identifies a potential host-directed intervention point, while its conclusions remain grounded in an in vitro model and do not establish efficacy in animals or people.
-
Tariquidar (XR9576): P-gp Inhibition in Research
2026-09-27
Tariquidar (XR9576) is a potent, noncompetitive P-glycoprotein inhibitor used to investigate ABC transporter inhibition and drug resistance research. A 2026 study links high extracellular viscosity to increased P-gp expression, but does not test tariquidar; the compound can therefore be considered an assay tool for separating transporter-mediated efflux from the study’s mechanical signaling pathway, not as a proven reversal of that pathway.
-
SGI-1027 and Everolimus in Renal Cancer
2026-09-26
A 2024 study reports that SGI-1027 induces methuosis-related lysosomal membrane permeability and cooperates with everolimus to suppress renal cancer models. The combination was associated with apoptosis and GSDME-dependent pyroptosis, suggesting a potential way to investigate non-apoptotic as well as apoptotic responses in renal cancer research.
-
Cyclopamine Workflows for Hh and Development Research
2026-09-26
Cyclopamine offers a practical way to perturb Smoothened-dependent Hedgehog signaling in cancer-cell assays and developmental models. This workflow-focused guide separates product-backed starting conditions from exploratory tissue studies, with controls and troubleshooting to help interpret results.